Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma
- PMID: 31242369
- DOI: 10.1056/NEJMc1905518
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma
Comment in
-
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.N Engl J Med. 2019 Jun 27;380(26):2581-2582. doi: 10.1056/NEJMc1905518. N Engl J Med. 2019. PMID: 31242370 No abstract available.
-
Immune Checkpoint Blockade plus Axitinib for Renal-Cell Carcinoma. Reply.N Engl J Med. 2019 Jun 27;380(26):2582. doi: 10.1056/NEJMc1905518. N Engl J Med. 2019. PMID: 31242371 No abstract available.
Comment on
-
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med. 2018 Apr 5;378(14):1277-1290. doi: 10.1056/NEJMoa1712126. Epub 2018 Mar 21. N Engl J Med. 2018. PMID: 29562145 Free PMC article. Clinical Trial.
-
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med. 2019 Mar 21;380(12):1116-1127. doi: 10.1056/NEJMoa1816714. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779529 Clinical Trial.
-
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.N Engl J Med. 2019 Mar 21;380(12):1103-1115. doi: 10.1056/NEJMoa1816047. Epub 2019 Feb 16. N Engl J Med. 2019. PMID: 30779531 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical